Bruce Sherman, MD, FCCP, FACOEM: Biosimilars and Costs for Employers

Bruce Sherman, MD, FCCP, FACOEM, chief medical officer of the National Alliance for Healthcare Purchaser Coalitions, discusses how biosimilars will play a role in controlling high drug costs for employers.
August 23, 2019


I think biosimilars will be helpful. I think there’s a little doubt from a cost standpoint. I think the willingness to embrace biosimilars in the [United States] has been slower than what we’ve seen, for example, in Europe, but I think they are here to stay. Hopefully the additional competition will help to further contribute to lower drug prices, and I think it’s just going to be a matter of time before those drugs are more readily available. 

I think, though, we also have to appreciate the significance not only of the drug but of the support services that may be coming from the respective pharmaceutical manufacturers that represent a wraparound offering for the specialty drugs that they manufacture. If those programs are providing additional value, I would hope that the biosimilar manufacturers could provide something comparable to those as well. 


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.